Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Birngruber, T; Tiffner, KI; Mautner, SI; Sinner, FM.
Dermal open flow microperfusion for PK-based clinical bioequivalence studies of topical drug products.
Front Pharmacol. 2022; 13: 1061178
Doi: 10.3389/fphar.2022.1061178
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Birngruber Thomas
- Sinner Frank Michael
- Co-Autor*innen der Med Uni Graz
- Mautner Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Topically applied drug products have experienced an extraordinary price increase in the United States, mostly due to a lack of generic products. Generic drug development is hindered by high costs and risks associated with clinical endpoint studies required to show bioequivalence (BE) of prospective generic products relative to their reference products. There is a continued need for cost- and time-efficient alternatives to clinical endpoint studies to determine BE of topically applied dermal drug products. Cutaneous PK-based BE studies present such an alternative and dOFM (dermal open flow microperfusion) has already been successfully used in several verifications studies to show an accurate and sensitive assessment of the rate and extent at which drugs become available in the skin. dOFM technology is discussed as well as the dOFM setup of clinical pilot and main studies to achieve BE assessment with a minimum number of participants and an outlook is given on the use of dOFM technology for other drug products.
- Find related publications in this database (Keywords)
- bioavailability
- topically applied dermal drug products
- verification study
- cutaneous PK
- dermal penetration
- PK-based BE study
- interstitial fluid
- systemic redistribution